Lv4
456 积分 2026-02-25 加入
Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?
7天前
已完结
Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer
9天前
已完结
Plying potency assays for immunotherapy of solid tumors
9天前
已完结
LBA4 Genomic and functional drivers of acquired resistance to TIL-ACT
10天前
已完结
In vitro inhibition of STAT5 signaling limits CD8⁺ T cell exhaustion and improves outcomes in adoptive T-cell therapy
10天前
已完结
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy
10天前
已完结
Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel
10天前
已完结
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
16天前
已完结
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
18天前
已完结
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
24天前
已完结
皖公网安备34019202002308
